Effect of Pulsed Estrogen Therapy on Hemostatic Markers in Comparison with Oral Estrogen Regimen in Postmenopausal Women

@article{Basurto2006EffectOP,
  title={Effect of Pulsed Estrogen Therapy on Hemostatic Markers in Comparison with Oral Estrogen Regimen in Postmenopausal Women},
  author={Lourdes Feria Basurto and Renata Saucedo and Arturo Zarate and Carlos Mart{\'i}nez and Elizabeth Gaminio and Elba Reyes and Marcelino Hern{\'a}ndez},
  journal={Gynecologic and Obstetric Investigation},
  year={2006},
  volume={61},
  pages={61 - 64}
}
Background/Aims: Hormone replacement therapy (HRT) is associated with an increased risk of thromboembolism dependent on the type of HRT; therefore, we compared therapy effects of intranasal with oral estrogens on coagulation and fibrinolysis markers in postmenopausal women. Methods: A randomized study in which 29 healthy hysterectomized women received intranasal 17β-estradiol or oral estrogens for 3 months. Results: There were no significant differences in the baseline characteristics between… 

Tables from this paper

Hormone therapy and hemostasis among postmenopausal women: a review

Current knowledge on the effects of HT on hemostasis is summarized, taking into account the route of estrogen administration, the daily dose and chemical structure of estrogens, and the pharmacologic class of progestogens.

Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial

During intranasal E2/NET therapy, changes in the coagulatory and fibrinolytic markers were to some extent less than those observed during oral therapy.

Effects of intranasal 17β-estradiol and raloxifene on lipid profile and fibrinogen in hypercholesterolemic postmenopausal women: A randomized, placebo-controlled clinical trial

Intranasal E2 exerts significant effects on lipid profile in hypercholesterolemic postmenopausal women and raloxifene has a greater impact on fibrinogen than intranasally E2 application.

Circulating levels of plasminogen activator inhibitor-1 are associated with metabolic syndrome rather than with menopause

The results of this study suggest that in women, MetS plays a more important role in the deterioration of the fibrinolytic mechanisms rather than their hormonal status, and the identification of cardio-metabolic factors is relevant to reduce the presence of thrombosis in post-menopausal women.

Menopausal women have hypofibrinolysis even in subclinical stage of atherosclerosis.

The findings suggest that fibrinolytic activity is low in the subclinical stage of atherosclerosis in premenopausal and postmenopausal women without apparent cardiovascular disease.

Efecto del tratamiento con estrógenos en la tensión arterial de mujeres posmenopáusicas

There is evidence of estrogen-therapy vasodilatation and hypotension effects, with clinical changes statistically significative; however it is recommendable that such estrogenic therapy must be individualized and attended in slender form.

Menopausal women have hypofibrinolysis even in subclinical stage of atherosclerosis.

The findings suggest that fibrinolytic activity is low in the subclinical stage of atherosclerosis in postmenopausal women and asymptomatic women with increased intima-media thickness had higher PAI-1 levels.

La enfermedad cardiovascular como amenaza actual para la mujer adulta mayor. La relación con los estrógenos

Several observational epidemiological studies have suggested that hormone therapy reduces the risk of coronary events in healthy postmenopausal women, but recent clinical studies failed to show such beneficial effect.

References

SHOWING 1-10 OF 29 REFERENCES

Effects of Hormone-Replacement Therapy on Fibrinolysis in Postmenopausal Women

Conjugated estrogen, both alone and in combination with medroxyprogesterone acetate, reduced mean plasma levels of PAI-1 from 32±34 ng per milliliter to 14±10 ng per m...

Effects of estrogen replacement therapy on thrombin generation.

Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.

Oral estradiol increased markers of fibrinolytic activity, decreased serum soluble E-selectin levels and induced potentially antiatherogenic changes in lipids and lipoproteins, and changed markers of coagulation towards hypercoagulability, and increased serum CRP concentrations.

Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein--a cross-sectional population survey.

It is concluded that different effects of oral and transdermal HRT on thrombotic and inflammatory variables may be relevant to their relative thromBotic risk; and it is suggested that this hypothesis should be tested in prospective, randomised studies.

Coagulation activation following estrogen administration to postmenopausal women.

Data indicate that low doses of oral estrogens frequently increase the amount of thrombin generated in vivo, which may help to explain the increased thrombotic risk that has been observed with higher doses of this medication.

The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables.

To delineate and compare the effects of perorally administered conjugated estrogens (CE) and transdermally administered estradiol (E2) in doses needed for hormone replacement therapy (HRT) on haemostasis parameters, 23 postmenopausal women were engaged in a study with an open cross-over design.

Fibrinolytic potential is significantly increased by oestrogen treatment in postmenopausal women with mild dyslipidaemia

Hormone replacement treatment with 17β-oestradiol for nine weeks significantly increased fibrinolytic potential in postmenopausal women with mild dyslipidaemia, suggesting that the cardioprotective effect of oestrogen may be mediated, in part, by an increase in fibrin plate activity.

Considerations in the choice of oral vs. transdermal hormone therapy: a review.

  • M. J. Minkin
  • Medicine
    The Journal of reproductive medicine
  • 2004
A review of the literature suggests that not all estrogens and progestins are alike, and alternative drugs, doses and delivery systems may exhibit better safety profiles than CEE/MPA, with no loss of efficacy.